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Summary  There  is  a  paucity  of  data  describing  acute  kidney  injury  (AKI)  following
transcatheter  aortic  valve  implantation  and  its  impact  on  mortality  remains  unknown.
We therefore  evaluate  the  incidence,  predictors  and  impact  of  AKI  following  transcat-RIFLE  criteria heter aortic  valve  implantation.  We  searched  MEDLINE  for  studies  from  2008  to  2013,
evaluating  AKI  after  transcatheter  aortic  valve  implantation.  All  studies  were  compared
according to  the  incidence,  predictors  and  impact  of  AKI  following  transcatheter  aortic
valve implantation.  AKI  was  diagnosed  according  to  the  Valve  Academic  Research  Consor-
tium deﬁnition  using  the  RIFLE  criteria.  Thirteen  studies  with  more  than  1900  patients
Abbreviations: AKI, Acute kidney injury; AKIN, Acute Kidney Injury Network; eGFR, Estimated glomerular ﬁltration rate; RRT, Renal
replacement therapy; TAVI, Transcatheter aortic valve implantation; VARC, Valve Academic Research Consortium.
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were  included.  AKI  occurred  in  8.3—57%  of  the  patients.  The  following  factors  were  associated
with AKI:  blood  transfusion;  transapical  access;  preoperative  creatinine  concentration;  periph-
eral vascular  disease;  hypertension;  and  procedural  bleeding  events.  The  30-day  mortality  rate
in patients  with  AKI  ranged  from  13.3%  to  44.4%  and  was  2—6-fold  higher  than  in  patients  with-
out AKI.  The  amount  of  contrast  agent  used  was  not  associated  with  the  occurrence  of  AKI.  AKI
is a  common  complication,  with  an  incidence  of  8.3—57%  following  transcatheter  aortic  valve
implantation.  Patients  with  AKI  had  higher  30-day  and  late  mortality  rates.  However,  AKI  was
related to  the  amount  of  contrast  volume  used  in  only  one  study.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
MOTS  CLÉS
Insufﬁsance  rénale
aiguë  ;
L’implantation  des
valves  aortiques  par
voie  percutanée  ;
Critères  RIFLE
Résumé  Il  y  a  peu  de  sources  qui  décrivent  l’incidence  d’une  insufﬁsance  rénale  aiguë  (IRA)
après l’implantation  des  valves  aortiques  par  voie  percutanée  et  son  inﬂuence  sur  la  mortalité.
Le but  de  cette  étude  est  d’évaluer  l’incidence,  les  facteurs  prédictifs  et  l’inﬂuence  d’IRA  sur
la mortalité.  Les  études  sur  ce  thème  publiées  entre  2008  et  2013  étaient  choisies  lors  d’une
analyse de  base  de  donnée  de  Medline.  Ces  études  étaient  comparées  entre-eux  en  ce  qui  con-
cerne l’incidence,  prédicteurs  et  l’inﬂuence  d’IRA  sur  la  mortalité.  Le  diagnostic  d’IRA  était
retenu selon  les  déﬁnitions  de  VARC  en  utilisant  les  critères  RIFLE.  Treize  études  étaient  inclues
dans notre  analyse.  Parmi  tous  les  patients  inclus,  l’IRA  était  développé  chez  8,3  %  à  57  %.  Les
facteurs suivants  étaient  liés  à  l’occurrence  de  L’IRA  :  la  transfusion  sanguine  ;  l’accés  transapi-
cal ;  la  créatinine  plasmatique  ;  l’arthropathie  oblitérante  periphérique  ;  la  tension  artérielle  ;
et l’hémorrhagie  intraopérative.  L’insufﬁsance  rénale  aiguë  est  une  complication  fréquente
avec une  incidence  de  8,3  %  à  57  %  chez  les  patients  ayant  une  implantation  de  valves  aortiques
par voie  percutanée.  Les  patients  présentant  une  IRA  ont  une  haute  mortalité  dans  les  premiers
30 jours  après  l′implantation  et  à  long  terme.  En  revanche,  la  dose  du  produit  de  contraste  n’est
pas un  facteur  de  risque  que  dans  seulement  une  étude.
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ackground
cute  kidney  injury  (AKI)  is  a  common  complication  in
atients  undergoing  cardiac  surgery,  occurring  in  up  to  30%
f  all  patients.  Moreover,  an  estimated  2—15%  patients
equire  renal  replacement  therapy  (RRT)  after  a  surgical  car-
iac  procedure,  with  an  in-hospital  mortality  rate  of  >  40%
1].
Transcatheter  aortic  valve  implantation  (TAVI)  has
merged  as  an  alternative  therapy  in  high-risk  patients  with
evere  aortic  stenosis.  Despite  the  encouraging  results  asso-
iated  with  TAVI,  post-procedural  AKI  remains  a  common
omplication,  with  a  wide  range  of  reported  incidences
2].
Since  the  introduction  of  the  Valve  Academic  Research
onsortium  (VARC)  criteria  in  January  2011  for  standardiz-
ng  deﬁnitions  of  clinical  endpoints  for  TAVI  [3],  a  recent
ooled  analysis  conﬁrmed  the  use  of  VARC  criteria  in  16
tudies  involving  3519  patients  [4].  The  diagnosis  of  AKI  was
ecommended  to  be  made  using  the  modiﬁed  RIFLE  crite-
ia.  The  recently  published  VARC-2  criteria  recommended
he  use  of  the  Acute  Kidney  Injury  Network  (AKIN)  classi-
cation  [5].  In  comparison  with  the  original  VARC  criteria,
he  timing  for  the  diagnosis  of  AKI  is  extended  from  72  hours
o  7  days,  to  ensure  the  association  with  the  procedure.
atients  with  AKI  should  be  followed  for  7  days  during  the
ndex  hospitalization.TAVI  procedures  involve  the  administration  of  contrast
gent;  the  need  for  rapid  pacing  with  resulting  hypoten-
ion  that  may  inﬂuence  renal  function  and  lead  to  acute
A
a
cs  droits  réservés.
idney  injury.  Moreover,  atherosclerosis  is  a  co-morbidity  in
he  majority  of  patients  undergoing  TAVI,  with  the  risk  of
mbolization  during  the  implantation.
Our  aim  in  this  review  was  to  analyse  the  incidence  of  AKI
mong  patients  undergoing  TAVI  in  the  literature.  In  addi-
ion,  we  intended  to  show  and  compare  all  the  predictors  of
KI  and  mortality  rates  in  the  appropriate  studies.  Moreover,
e  tried  to  assess  whether  contrast  agent  has  an  inﬂuence
n  AKI  after  TAVI.
ethods
e  performed  a  web-based  search  on  PubMed  to  ﬁnd  articles
escribing  AKI  after  TAVI.  The  following  keywords  were  used:
ranscatheter  aortic,  acute  kidney  injury  and  VARC.  Only
rticles  that  described  AKI  incidence,  prognostic  factors  and
ortality  in  details  were  evaluated.
eﬁnition of acute kidney injury
KI  was  deﬁned  according  to  the  RIFLE  criteria  or  the  VARC
riteria  (using  the  modiﬁed  RIFLE  criteria)  (Table  1)  [3].  The
ecision  to  undertake  RRT  during  the  index  hospitalization
as  made  by  the  intensivist  responsible  for  the  patient.
mong  all  the  reviewed  studies,  four  used  the  RIFLE  criteria
nd  six  used  the  VARC  criteria.  Only  one  study  used  the  AKIN
lassiﬁcation  [6].
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Table  1  Acute  kidney  injury,  according  to  the  Valve  Academic  Research  Consortium  deﬁnition.
Stage  Change  in  serum  creatinine  (72  hours)  compared  with  baseline
Stage  1  Increase  in  serum  creatinine  to  150—200%  (1.5—2.0-fold  increase  compared  with  baseline)  or  increase
of  >  0.3  mg/dL  (>  26.4  mmol/L)
Stage  2  Increase  in  serum  creatinine  to  200—300%  (2.0—3.0-fold  increase  compared  with  baseline)  or  increase
of  >  0.3  mg/dL  (>  26.4  mmol/L)  but  <  4.0  mg/dL  (<  354  mmol/L)
Stage  3a Increase  in  serum  creatinine  to  ≥  300%  (>  3.0-fold  increase  compared  with  baseline)  or  serum
creatinine  ≥  4.0  mg/dL  (≥  354  mmol/L),  with  acute  increase  of  ≥  0.5  mg/dL  (44  mmol/L)
a Patients receiving renal replacement therapy are considered to meet stage 3 criteria, irrespective of other criteria.
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Continuous  variables  are  presented  as  means  ±  standard
deviations  or  medians  with  interquartile  ranges.  Categorical
variables  are  presented  as  frequencies  (percentages).
Results and discussion
Our  systematic  search  found  13  studies  with  more  than
1900  patients  (aged  79—84  years)  who  underwent  TAVI  for
severe  aortic  stenosis  between  2006  and  2012  (Fig.  1).  The
EuroSCORE  ranged  from  18%  to  34%  and  the  STS  score  ranged
from  6%  to  14%  (Table  2).  All  studies  were  published  between
2010  and  2013.
Figure 1. Flow chart.
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Ancidence of acute kidney injury after
ranscatheter aortic valve implantation
ccording  to  the  evaluated  studies,  the  incidence  of  AKI
fter  TAVI  ranged  from  8.3%  to  57%  (Table  3).  RRT,  however,
as  required  in  2—40%  of  all  patients.  The  incidence  of  AKI
as  highest  in  the  studies  by  Strauch  et  al.  (42%)  [7]  and
aia  et  al.  (57%)  [8]. Of  note,  in  the  latter  study,  87.3%  of
ll  the  patients  were  presented  with  chronic  kidney  disease.
nterestingly,  only  4.9%  underwent  RRT  and  the  incidence  of
KI  was  two-fold  higher  in  patients  undergoing  transapical
AVI  than  in  those  undergoing  transfemoral  TAVI.
A  lower  incidence  of  AKI  was  observed  in  the  study  by
enereux  et  al.  [9]. The  authors  compared  patients  in  stages
 and  1  (AKI  0—1)  versus  patients  in  stages  2  and  3  (AKI  2—3),
ccording  to  the  VARC  criteria.  AKI  occurred  in  only  8.3%
f  the  218  evaluated  patients.  However,  this  study  popula-
ion  exhibited  the  highest  30-day  and  1-year  mortality  rates
44.4%  and  55.6%,  respectively).  In  their  study,  Genereux
t  al.  deﬁned  AKI  stages  2  and  3  as  signiﬁcant  AKI,  which
xplains  the  lower  rate  of  AKI  after  TAVI.  If  the  authors
ncluded  patients  with  stage  1  AKI,  the  incidence  of  AKI
ncreased  to  34.4%.
RRT  as  rescue  in  patients  with  oliguria  and  anuria  ranged
rom  0%  to  18.6%.  The  decision  to  undertake  RRT  during
he  index  hospitalization  was  made  by  the  intensivist  and
ould  not  be  compared  between  studies.  Approximately
ne  quarter  of  patients  with  AKI  underwent  RRT.  More-
ver,  patients  who  had  RRT  had  a  worse  outcome  than  AKI
atients  who  did  not  have  RRT.  Thus,  is  RRT  a  prognostic
actor  for  mortality  after  AKI?  Results  from  the  study  by
an  Linden  et  al.  showed  a  nine-fold  higher  mortality  in
hose  who  had  RRT.  Additionally,  in  the  multivariable  anal-
sis,  serum  creatinine  >  1.1  (mg/dL),  estimated  glomerular
ltration  rate  (eGFR)  <  60  (mL/min/1.73  m2),  blood  trans-
usion  >  5  units  and  leucocyte  count  >  12  g/L  remained  as
ndependent  predictors  of  RRT  during  the  index  hospitaliza-
ion  [10].
redictors of acute kidney injury
atients,  undergoing  TAVI,  were  presented  with  severe
o-morbidities,  such  as  chronic  obstructive  pulmonary  dis-
ase,  hypertension,  diabetes,  peripheral  vascular  disease,
orcelain  aorta,  coronary  heart  disease,  previous  cere-
rovascular  disease  and  chronic  renal  failure.  Predictors  of
KI  were  baseline  creatinine  concentration  [2,6,11], blood
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Table  2  Baseline  characteristics.
Study  Patients(n)  Access
(%)
Age
(years)a
Baseline
creatinine
(mol/L)a
Baseline
GFRa
Contrast
medium
used
(mL)a
EuroSCORE
(%)a
STS  score
(%)a
Elhmidi  et  al.  [2]  234  TF:  65.2;
TA:  24;
TaA:2.2
81.8  ±  6.4  124.9  ±  43  NA  144  ±  59  22.55  ±  14.77  7.04  ±  3.6
Barbash  et  al.  [14]  165  TF:  50;  TA:
50
84  ±  5  NA  43  ±  18  98  ±  46  NA  11  ±  4
Sinning  et  al.  [6]  70  TF:  100  79.9  ±  6.8  NA  NA  207  ±  70  31.2  ±  17.6  9.3  ±  6.1
Saia  et  al.  [8]  102  NA  83.7  ±  5.3  NA  NA  111  ±  35  22.6  ±  12.4  8.2  ±  4.1
Genereux  et  al.  [9]  218  TF:  64,2;
TA:  35,7
84.0  ±  7.4  123.2  ±  52.8  52.9  ±  19.2  122.6  ±  96  NA  12.8  ±  4.3
Nuis  et  al.  [13]  118  NA  83  (76—85)  119  ±  71  54  ±  20  213  ±  56  18.4
(8.7—30.5)
9.3
(3.9—13.8)
Van  Linden  et  al.  [10]  270  TA:  100  82  ±  5.8  167  ±  44  44.3  ±  15.9  110  ±  21  31.4  ±  15.6  12.1  ±  7.4
Strauch  et  al.  [7]  28  TA:  100  82.1
(71—88)
NA  NA  NA  19.01
(5.1—77.4)
13.6
(3.2—26)
Bagur  et  al.  [12]  213  TF:  36;  TA:
64
84  ±  7  102.9  ±  44  70  (49—80)  79  ±  55  34.3  +  21.8  NA
Aregger  et  al.  [16]  60  TF:  79;  TA:
21
83  ±  6  123  ±  72  57  ±  33  242  ±  101  25  ±10  NA
Khawaja  et  al.  [15]  248  TF:  32.6;
TA:  44.9;
TaA:  22.5
83.3 ±  6.9  134.7  ±  74.5  43.2  ±  26.1  110.35  ±  47.5  25.3  ±  16.1  NA
Alassar  et  al.  [11]  79  NA  84  (78—87)  NA  NA  NA  NA  NA
Gebauer  et  al.  [25]  150  TF:  64;  TA:
36
81  ±  7  126.4  ±  59.2  51  ±  17  147  ±  71  24  ±  15  6.0  ±  3.5
GFR: glomerular ﬁltration rate (mL/min/1.73 m2); NA: not available; TA: transapical; TaA: transaortic; TF: transfemoral.
a Data are mean ± standard deviation or median (interquartile range).
TAVI  and  acute  kidney  injury  
Table  3  Incidence  of  acute  kidney  injury  and  renal
replacement  therapy.
Study  AKI  RRT
Elhmidi  et  al.  [2]  46  (19.6)  24  (10.3)
Barbash  et  al.  [14]  24  (14.6)  0
Sinning  et  al.  [6] 20  (26.0) 28  (40.0)
Saia  et  al.  [8] 42  (41.7) 5  (4.9)
Genereux  et  al.  [9] 18  (8.3) 9  (4.1)
Nuis  et  al.  [13]  22  (19.0)  2  (2.0)
Van  Linden  et  al.  [10]  42  (16.1)  42  (15.7)
Strauch  et  al.  [7]  16  (57.0)  6  (21.0)
Bagur  et  al.  [12]  25  (11.7)  3  (1.4)
Aregger  et  al.  [16]  15  (28.0)  4  (7.4)
Khawaja  et  al.  [15]  89  (35.9)  4  (10.0)
Alassar  et  al.  [11]  9  (12.3)  NA
Gebauer  et  al.  [25]  30  (20.0)  6  (4.0)
Data are number (%); AKI: acute kidney injury; NA: not available;
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transfusion  [12,13],  transapical  approach  [8,14],  peripheral
vascular  disease  [15],  logistic  EuroSCORE  [13],  diabetes  mel-
litus  [11,15],  and  contrast  agent  [10]  (Table  4).
Saia  et  al.  showed  that  AKI  was  related  to  the  TAVI  access.
Patients  in  whom  the  transapical  access  was  used  exhib-
ited  more  AKI  than  those  in  whom  the  transfemoral  access
was  used  (66.7%  vs  30.3%;  P  =  0.004),  even  after  adjustment
for  baseline  differences  [8].  Moreover,  in  the  multivariable
analysis,  the  transapical  assess  remained  as  an  independent
predictor  of  AKI,  with  an  incremental  risk  between  4.7-
fold  and  5.2-fold.  Similarly,  Aregger  et  al.  found  a  higher
e
p
i
o
Table  4  Predictors  of  acute  kidney  injury.
Study  Variable  
Elhmidi  et  al.  [2]  Baseline  creatinine  
Barbash  et  al.  [14]  Transapical  access  
Sinning  et  al.  [6]  Baseline  creatinine  >  1.58  mg/dL
Saia  et  al.  [8]  Transapical  access  
Genereux  et  al.  [9]  Life-threatening  bleeding  
Nuis  et  al.  [13]  Logistic  EuroSCORE  
Blood  transfusion  
Previous  myocardial  infarction  
Leucocyte  count  
Van  Linden  et  al.  [10]  Thrombocytopoenia  
Contrast  agent  
Leucocyte  count  >  12  g/L  for  >  2  
Bagur  et  al.  [12]  Blood  transfusion  
Hypertension  
COPD  
Khawaja  et  al.  [15]  PVD  
Diabetes  mellitus  
Chronic  kidney  disease  
Peak  transaortic  gradient  
Alassar  et  al.  [11]  Baseline  creatinine  >  104  mol/L
Diabetes  mellitus
CI: conﬁdence interval; COPD: chronic obstructive pulmonary disease; 137
ncidence  of  AKI  in  patients  undergoing  transapical  TAVI  (47%
s  8%;  P =  0.003).  It  is  of  note  that  the  transapical  approach
as  used  in  only  12  patients  —  a  very  small  number  from
hich  to  draw  a conclusion  [16].
Several  investigators  have  shown  a  relatively  higher
ncidence  of  AKI  after  TAVI  that  was  related  to  the  severe  co-
orbidities  of  the  patients.  However,  it  is  unclear  which  of
hese  co-morbidities  contribute  most  to  deteriorated  renal
unction  after  TAVI.  Most  of  the  studies  reviewed  performed
nivariate  and  multivariable  Cox  regressions  to  analyse  such
ariables  as  risk  factors  for  AKI  after  TAVI.  Several  studies
ound  a  correlation  between  AKI  and  baseline  renal  func-
ion  [2,6,15].  For  instance,  the  recently  published  study  by
lassar  et  al.  found  a  preoperative  creatinine  concentra-
ion  >  104  mol/L  to  be  a  risk  factor  for  AKI  [11].  However,
inning  et  al.  found  that  a  baseline  creatinine  concentra-
ion  ≥  1.58  mg/dL  was  a predictor  for  developing  AKI  (hazard
atio  3.9,  95%  conﬁdence  interval  1.6—9.5;  P  =  0.002)  [6].
n  our  previous  study,  baseline  serum  creatinine  concentra-
ion  remained  the  only  predictor  for  AKI  in  the  multivariable
nalysis  (odds  ratio  3.7,  95%  conﬁdence  interval  1.24—11.3;
 =  0.019)  [2].
Other  studies  have  demonstrated  that  blood  transfusion
s  a  predictor  of  AKI  [12,13,16,17]. Preserved  red  blood  cells
ndergo  progressive  functional  and  structural  changes,  lead-
ng  to  a  deterioration  in  red  blood  cell  function  and  viability,
nd  accumulate  free  iron  and  pro-inﬂammatory  agents;  all
f  these  changes  may  favour  renal  dysfunction,  particularly,
n  patients  with  advanced  age  with  peripheral  vascular  dis-
ase  and  diabetes  mellitus  [18,19]. Bagur  et  al.  showed  that
atients  who  had  received  red  blood  cells  had  a  >  three-fold
ncrease  in  AKI  occurrence  [12]. Saia  et  al.  found  that  61.9%
f  the  patients  presented  with  AKI  after  TAVI  received  red
HR  (95%  CI)
3.7  (1.24—11.3)
2.9  (1.03—8.29)
 3.9  (1.6—9.5)
4.7  (1.6—13.89)
5.87  (1.84—14.76)  adjusted
1.08  (1.01—1.14)
1.29  (1.01—1.7)
5.7  (1.64—19.9)
1.18  (1.02—1.37)
4.4  (1.6—12.2)
2.3  (1.0—4.9)
days  postoperatively  2.8  (1.3—6.0)
3.47  (1.3—9.29)
4.66  (1.04—20.87)
2.64  (1.10—6.36)
2.94  (1.34—6.44)
3.17  (1.67—6.05)
1.57  (1.11—2.21)
0.98  (0.97—0.99)
 1.04
6.7
HR: hazard ratio; PVD: peripheral vascular disease.
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Table  5  Mortality  rate  in  acute  kidney  injury  patients  and  all  patients.
Study  AKI  patients  (%)  All  patients  (%)
30  days 1  year 30  days 1  year
Elhmidi  et  al.  [2]  15.2  NA  NA  NA
Barbash  et  al.  [14] 29  NA  10.3  NA
Sinning  et  al.  [6] NA  70  10  26
Saia  et  al.  [8] NA  11.8  4.9  NA
Genereux  et  al.  [9]  44.4  55.6  6.4  NA
Nuis  et  al.  [13]  23  55  8  NA
Van  Linden  et  al.  [10]  26.2  55  8.8  NA
Strauch  et  al.  [7]  25  NA  NA  NA
Bagur  et  al.  [12]  28  NA  9.8  NA
Aregger  et  al.  [16]  13.3  NA  NA  NA
Khawaja  et  al.  [15]  13.5  31.5  NA  NA
Gebauer  et  al.  [25]  29  43  NA  NA
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lood  cell  transfusion  intraoperatively  compared  with  only
1.7%  of  the  patients  with  no  AKI  (P  =  0.04)  [8].  In  this  latter
tudy,  red  blood  cells  were  not  a  predictor  of  AKI  after  TAVI.
imilarly,  in  the  study  by  Nuis  et  al.,  patients  who  developed
KI  underwent  signiﬁcantly  more  red  blood  cell  transfusion
han  those  with  no  AKI  (2.7  ±  3.6  units  vs  1.1  ±  1.3  units;
 =  0.001)  [13,17].
Some  authors  have  suggested  that  severe  hypoten-
ion,  induced  by  ventricular  rapid  pacing,  may  lead
o  deterioration  in  renal  perfusion  and  thereby,  renal
ysfunction,  with  an  increased  risk  of  AKI.  Ventricular
apid  pacing  is  a  ‘‘conditio  sine  qua  non’’  for  aortic
alvuloplasty,  balloon-expandable  valve  deployment  and
ost-implantation  dilation.  Interestingly,  Bagur  et  al.  found
o  correlation  between  the  number  of  rapid  pacing  runs  and
he  occurrence  of  AKI  [12].
ontrast agent and the risk of acute kidney
njury
n  previous  studies,  contrast  agent  volume  >  100  mL  was
ssociated  with  higher  contrast-induced  nephropathy  and
ortality  after  coronary  interventions  [20—22].  The  volume
f  contrast  agent  given  during  the  implantation  varied  from
9  ±  55  mL  to  242  ±  101  mL.  The  contrast  agent  was  associ-
ted  with  AKI  in  only  one  study  [10];  patients  with  AKI  had
ore  contrast  agent  than  those  without  AKI  [10].  Moreover,
atients  undergoing  RRT  needed  more  contrast  agent  than
hose  without  RRT  (139  ±  136  mL  vs  93  ±  35  mL;  P  <  0.001).
ontrast  agent  >  99  mL  was  an  independent  predictor  of  AKI.
imilarly,  Strauch  et  al.  assumed  an  association  between
ontrast  agent  and  AKI  [7].  Of  note,  the  latter  study  included
nly  28  patients  undergoing  TAVI;  the  small  number  meant
hat  Cox  regression  analysis  was  not  possible.  Differences
n  the  relationship  between  the  amount  of  contrast  used
n  each  study  and  the  occurrence  of  AKI  are  noteworthy,
s  all  TAVI  procedures  require  contrast  agent.  One  reason
or  this  may  be  associated  with  the  fact  that  patients  with
nown  renal  failure  or  a  higher  preoperative  serum  creat-
nine  concentration  receive  a  smaller  volume  of  contrast
gent  than  patients  without  pre-existing  renal  failure.
t
t
t
uNonetheless,  efforts  to  reduce  the  amount  of  contrast
gent  during  implantation  should  be  made.  The  use  of
chocardiographic  or  magnetic  resonance  imaging  guidance
n  valve  deployment  [23,24]  may  reduce  the  amount  of  con-
rast  agent  used  in  TAVI.
cute kidney injury and mortality
n  all  studies,  patients  who  developed  AKI  after  TAVI  exhib-
ted  a  2—6-fold  higher  mortality  rate.  The  30-day  and  1-year
ortality  rates  ranged  from  8.8%  to  44.4%  and  31.5%  to
5.5%,  respectively.  Moreover,  mortality  increased  in  those
atients  undergoing  RRT  of  ≥  10%  (Table  5).
All  studies  have  shown  AKI  to  be  a  powerful  predictor
f  mortality  at  short-  and  long-term  follow-up  after  TAVI
2,6,12—15]. AKI  was  associated  with  a  4-fold  higher  mor-
ality  rate  and  this  association  persisted  independent  of
aseline  characteristics  and  periprocedural  complications
uring  TAVI  [12].  One  may  suggest  that  AKI  is  a  marker
or  multiorgan  failure  and  is  therefore  associated  with  a
igher  mortality  rate.  Patients  developing  AKI  subsequently
ad  a  systemic  inﬂammatory  response  syndrome  (60%  vs
1%;  P  =  0.002),  which  may  explain  the  pathophysiology  of
 higher  leukocyte  count  and  thrombocytopoenia,  as  stated
n  previous  studies  [6,13].
mprovement in renal function after TAVR
he  reviewed  studies  assessed  the  occurrence  of  AKI  and
ts  impact  on  mortality.  Nonetheless,  a  few  reports  showed
n  important  improvement  in  renal  function  in  patients  fol-
owing  TAVI  [2,12]. Bagur  et  al.  showed  no  changes  in  eGFR
n  1%  of  the  patients,  48  hours  after  TAVI,  but  a  signiﬁcant
ncrease  in  eGFR  in  60%  of  the  patients  [12]. Of  note,  AKI
as  deﬁned  according  to  the  RIFLE  criteria  within  48  hours
fter  the  procedure.  However,  this  48-hour  window  is  not
dequate  for  assessing  the  occurrence  of  AKI,  given  that
he  creatinine  concentration  peak  in  patients  with  AKI  is
ypically  late  (3—7  days)  [2,14]. Similarly,  Saia  et  al.  found
hat  GFR  increased  in  58%  of  the  patients  and  remained
nchanged  in  4%  [8].  In  accordance  with  these  studies,  we
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[TAVI  and  acute  kidney  injury  
reported  in  our  previous  study  an  increase  in  eGFR  in  59.6%
of  all  the  patients,  while  3.5%  showed  no  changes  in  eGFR
[2].
Conclusion
Acute  kidney  injury  is  a  common  complication,  with  an  inci-
dence  of  8.3%  to  57%  in  patients  following  TAVI.  Patients
developing  AKI  after  TAVI  exhibited  a  2—6-fold  higher  mor-
tality  rate.  A  higher  preoperative  creatinine  concentration,
blood  transfusion  and  peripheral  vascular  disease  are  inde-
pendent  predictors  of  AKI  after  TAVI.
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